Akero Therapeutics Inc.

About Akero Therapeutics Inc.

Akero Therapeutics is a biotechnology company focused on pioneering novel therapies to transform the lives of people with serious metabolic diseases, particularly through their flagship program for metabolic dysfunction-associated steatohepatitis (MASH).

Products & Services

Efruxifermin (EFX):A differentiated, potentially best-in-class treatment under development for metabolic dysfunction-associated steatohepatitis (MASH).

Specialties

Metabolic Diseases Metabolic Dysfunction-Associated Steatohepatitis (MASH) Clinical Trials for Investigational Drugs

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 366900000 MR: - FA: approximately $366.9 million FAN: 366900000	D: 2024-03-08 FD: 2024-03-08	4 investors
2	RT: Public Offering T: - FT: Public Offering	A: 319000000 MR: - FA: $319.0 million FAN: 319000000	D: 2024-03-08 FD: 2024-03-08	4 investors
3	RT: Public Offering T: - FT: Public Offering	A: 319000000 MR: - FA: $319.0 million FAN: 319000000	D: 2024-03-05 FD: 2024-03-05	4 investors
4	RT: Public Offering T: - FT: Public Offering	A: 300000000 MR: - FA: $300.0 million FAN: 300000000	D: 2024-03-04 FD: 2024-03-04	4 investors
5	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 220000000 MR: - FA: 220.0 Million FAN: 220000000	D: 2023-05-16 FD: 2023-05-16	10 investors

Public Offering Latest

2024-03-08

$366.9M

4 investors (Pro only)

Public Offering 2024-03-08

$319.0M

Public Offering 2024-03-05

$319.0M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

B

Brittany de Temple

Vice President of Development Operations

D

Dominick Villani, Ph.D.

Vice President, Quality

J

John Schembri

Senior Vice President, Head of Finance

L

Libette Luce

Vice President of Regulatory Affairs

M

Matthew Johnson, Ph.D.

Vice President, Drug Substance

M

Meena Jain, M.D., Ph.D.

Vice President of Clinical Development

View 32 more team members with Pro

Unlock Full Team Directory

Recent News